Mentor/Valeant Collaborate on Physician Loyalty Program

Mentor Worldwide LLC, the U.S. market leader in breast aesthetics, today announced that it has entered into a collaboration agreement with Valeant’s Medicis division, a leader in facial injectables and professional skincare. Per the terms of the agreement, Mentor and Medicis will form a joint physician loyalty program called the M2VP Program (Medicis-Mentor Valued Partner Program), which will include the MENTOR line of breast implant products for the aesthetics market and Medicis non-reimbursed facial aesthetics products, including neurotoxin, fillers, and skincare. The agreement has a five-year term and is for the U.S., subject to any geographical expansion that may be agreed upon by the parties.

"We believe the creation of a combined loyalty program allows both organizations to deliver more value and choice to plastic surgeons operating in an increasingly competitive market,” said David J. Wilson, Worldwide President, Mentor Worldwide LLC. “By incorporating the best features of other programs, we’ve created a premier loyalty program that includes Mentor’s leading breast implant products – and provides product savings and benefits to our customers."

“This will be an extremely valuable program for me," said Tracy Hankins, M.D., a board certified plastic surgeon in Nevada. "I have utilized products from both companies for years, and now I can earn valuable rebates and rewards in one easy to understand loyalty program.”

The M2VP program rewards utilization of various products across the Mentor and Medicis portfolios. The M2VP program allows participating members to earn points, which establish status within the program and can be redeemed for product purchases. In designing the program, Mentor and Medicis sought to address many of the issues that physicians believe exist with other programs.

Suggested Articles

The device allows medical aesthetics clinicians to treat a wider range of skin conditions.

The organization’s survey results reveal the most sought-after procedures during the COVID-19 pandemic.

He was most recently managing director of the SHIELD innovation center of Nestlé Skin Health/Galderma in New York City.